Netilmicin

Summary

Netilmicin (CHEMBL1572) is an approved small molecule (ATC J01GB07); indicated across 3 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01GB07 (+1 more)
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 475.6 Da · C21H41N5O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1572
Name	Netilmicin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	441306
ATC	J01GB07, S01AA23
Molecular formula	C21H41N5O7
Molecular weight	475.6
InChIKey	CIDUJQMULVCIBT-MQDUPKMGSA-N

SMILES: CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N

IUPAC name: (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

Also known as: Netilmicin, Netilmicina, Netilmicine, Netira, NSC-759586, netilmicin, netilmycin, NETILMICINE, NETILMICIN

Parent form; salt/anhydrous children: CHEMBL3989829

Patent coverage: 167 distinct patent families (363 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bacterial 70S ribosome.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P02358	7.7	IC50	20	nM	CHEMBL_ACT_19126755

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01559753	PHASE4	COMPLETED	Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kana	CPIC	MT-RNR1		yes

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).